PETRI DISH PERSPECTIVES

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong.

We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the landmark Phase 3 RASolute 302 results that showed unprecedented overall survival in metastatic pancreatic cancer, earned a Plenary presentation at ASCO 2026, and triggered an FDA NDA review.

But this is also a story about the pressure of building an ambitious company with no revenue, nearly $1 billion in annual R&D spend, and a failed $30 billion acquisition attempt with Merck that sent the stock crashing 26% in a single day. Revolution walked away from the deal. The question now is whether that confidence was prescient or premature.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #RevolutionMedicines #RAS #KRAS #Oncology #PancreaticCancer #LungCancer #Daraxonrasib #Biotech #DrugDiscovery #PrecisionOncology #CancerResearch #FDA #LifeSciences #Healthcare #BiotechTok #BiotechNews

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

After training as a physician, earning an MBA from Wharton, and co-founding Sonara Health, a digital health company that raised over $10 million from the NIH, VCs, Dr. Avinash Jayaraman could have gone in almost any direction. He chose to focus on one of the most urgent and underserved crises in adolescent health: the mental health epidemic driven by technology overuse.

In this episode, Dr. Jayaraman unpacks why screen time and social media have become a clinical problem, not just a parenting debate, what it actually takes to build a mental health startup for kids and teens in a system that has historically ignored them, and why he believes the solution has to combine real clinical care with a deep understanding of how technology rewires the adolescent brain.

Check out Blue Light Health: https://bluelighthealth.com/

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BlueLightHealth #MentalHealth #AdolescentHealth #DigitalHealth #TechAddiction #ScreenTime #HealthTech #Startups #Healthcare #BiotechTok

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026!

This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless dealmaking streak with a $3.25 billion InnoCare partnership. On the regulatory front, the FDA approved the first-ever treatment for Sanfilippo syndrome, a first-in-class Parkinson's drug, the world's first radioligand equivalent, and a new once-weekly insulin, a remarkable month for patients with rare and chronic diseases. ADARx raised $446 million in one of biotech's largest IPOs of the year, and Electra Therapeutics upsized its own raise to $350 million, signaling that the IPO window remains open for the right science. Meanwhile, Novo's total workforce cuts reached 13,000 and BMS continued trimming headcount, a reminder that even the industry's biggest players are restructuring for what comes next. The bigger story is unmistakable: China is no longer just manufacturing drugs for the West, it is discovering them, and the deals signed this month prove that Big Pharma has fully accepted that reality.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map.

We break down how Hengrui made the pivot from generics to innovation, why Western pharma is now writing billion-dollar checks for Chinese science, and the controversies, including a scathing FDA warning letter and corruption scandals, that complicate the story.

Because Hengrui wasn't hiding. It was building, the whole time.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Hengrui #ChinaBiotech #Pharma #Biotech #DrugDiscovery #NovoNordisk #GSK #GLP1 #Oncology #LifeSciences #Healthcare #BiotechInnovation #PharmaceuticalIndustry

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

After years of running a school on the rigid rhythm of bells, Dr. John Murphy walked away from K-12 education and into something he never trained for: performing history at bars.

In this episode, John unpacks how a credentialed academic builds an audience outside the walls of a traditional institution, why humor and analogies are the secret weapons of great storytelling, and what it actually takes to turn expertise into something people will pay a bar tab to hear. Quick note: this one's a bit of a departure from our usual biotech and pharma coverage, but the story was too good to pass up.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Edutainment #ScienceCommunication #ContentCreator #PersonalBrand #PublicSpeaking #HistoryLecture #Storytelling #ChicagoEvents #CreatorEconomy

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore Anew Labs, the AI drug discovery company that emerged from one of the most unexpected places in biotech: ByteDance, the parent company of TikTok. Fresh off a $290 million raise at a $1.5 billion valuation, Anew is betting that artificial intelligence can fundamentally change how we discover medicines, not by making existing drug development slightly faster, but by rethinking the entire discovery process from the ground up.

We'll break down why ByteDance got into drug discovery in the first place, how Anew's AI platforms work across protein structure prediction, molecular design, and antibody optimization, and what makes its first-in-class small molecule IL-17 program one of the most scientifically ambitious bets in the company's pipeline. We'll also explore the broader competitive landscape, from Anthropic's $400 million acquisition of Coefficient Bio to NVIDIA and Eli Lilly's $1 billion co-innovation lab and what it means that Big Tech is no longer just building tools for pharma, but trying to become the drug company itself.

But the biggest question hanging over all of it remains unanswered: can AI actually discover drugs? Not molecules that look promising on a computer. A medicine that works in humans, survives clinical development, gets approved, and changes patient outcomes. We'll dig into why the proof hasn't arrived yet and why Anew is one of the most important tests of that question in the world right now.

Because the next breakthrough in medicine may not come from a traditional pharmaceutical company. It may come from an algorithm trained on biology and a team willing to bet everything that the computer got it right.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #AnewLabs #AIDrugDiscovery #ByteDance #Biotech #Biotechnology #Pharma #ArtificialIntelligence #DrugDiscovery #MachineLearning #LifeSciences #Healthcare #Isomorphic #Anthropic #NVIDIA #EliLilly #BispecificAntibody #Immunology #AIinHealthcare #BiotechInnovation #PrecisionMedicine #DrugDevelopment

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

After a career spent racing against the clock in emergency rooms, Dr. Elliot Justin found himself chasing a very different kind of vital sign, one most men never think to track. Before FirmTech, he built and exited a telemedicine company and a physician staffing group. But it's the wearable ring, designed to quietly monitor erectile function, that's turning heads for an unexpected reason: the data may predict cardiovascular risk years before symptoms ever show up.

In this episode, Dr. Justin unpacks how a symptom most men are taught to ignore became one of the most promising early-warning signals in preventive cardiology and what it actually takes to build a hardware company in one of medicine's most stigmatized categories. 

Check out FirmTech: https://myfirmtech.com/

Use MANEAD15 to receive a discount on FirmTech products.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #HealthTech #DigitalHealth #WearableTech #CardiovascularHealth #MensHealth #PreventiveMedicine #Biotech #HealthInnovation #StartupFounder #MedTech #FirmTech

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation.

We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster.

We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global?

From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine?

Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026!

This month was defined by major dealmaking, a resurgence in biotech financing, and growing questions about where the global biotech industry is headed. Roche made a $2.5 billion bet on Hanmi, McKesson acquired Precision Medicine Group for $2.25 billion, and the investors behind Metsera quickly returned with Sentivera and a licensing deal worth up to $1.5 billion. Meanwhile, companies including Apnimed, Attovia, and Braveheart kept the IPO market active, suggesting that investor appetite for biotech may be continuing to recover. On the regulatory front, a series of FDA approvals expanded treatment options across HIV, autoimmune disease, cardiovascular disease, cancer, and rare disorders, while three reported deaths in Chinese gene therapy trials sparked renewed debate in Washington about clinical-trial oversight and the FDA's reliance on international data. The bigger story is clear: biotech is becoming increasingly global, capital-intensive, and interconnected, where success depends not only on great science, but also on manufacturing, financing, regulation, and strategic partnerships.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation.

We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production.

But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy.

Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.